ABSTRACT
Since the first successful allogeneic marrow transplant (1), prevention and management of acute graft-versus-host disease (aGVHD) have remained two of the major problems of stem cell transplantation. A better understanding of the pathophysiology of aGVHD and the human leukocyte antigen (HLA) barrier, as well as the development of more effective and selective immunosuppressive agents, are crucial to reducing the morbidity and mortality of aGVHD.
